cbdMD 2024财年每股收益同比增长至-1.79美元,收入同比下降至1948万美元

财报速递12-19
2024财年财务亮点如下: 2024财年净销售额总计1948万美元,较2023财政年度下降19.1%。本年度的毛利润与2023财年持平,均为62%。2024财年的运营亏损为330万美元,而2023财年的运营亏损为2240万美元。尽管收入下降,但2024财年非GAAP调整后的运营亏损为150万美元,而2023财年为550万美元。 2024财年下半年的非GAAP调整后EBITDA亏损降至20万美元,而上年同期为120万美元。 2024财年归属于普通股股东的净亏损约为770万美元,每股亏损1.79美元,而2023财年为2690万美元,每股亏损13.30美元。2024财年的改善主要归因于管理层对提高盈利能力的持续努力以及2023年期间的1320万美元无形资产减值。在2024年9月30日,我们的营运资本约为110万美元,现金约240万美元(包括470万美元的A系列累计股息支付),而2023年9月30日我们的营运资本约为340万美元,现金约180万美元(包括67万美元的A系列累计股息支付)。我们报告称2024财年直销(DTC)净销量为1570万美元,占总净销量的80.4%,较2023财年减少了390万美元,下降了19.9%。截至年度报告提交日期,大部分票据已转换,票据余额约为36万美元。考虑到我们在2024年9月30日现金余额为240万美元以及持续的现金消耗率,管理层相信公司在进入2025年日历年时具备较强的流动性。根据NYSE美国公司指南第610(b)条款的披露要求,cbdMD报告称其截至2024年9月30日的财年经审计合并财务报表包含了一段解释性段落,说明了其注册的独立会计师事务所关于cbdMD继续作为持续经营的能力的审计意见。本公告不代表对cbdMD财报或其截至2024年9月30日的财年10-K年报作出任何更改或修正。我们将于2024年12月18日(星期三)美东时间下午4:20举行电话会议,讨论2024年9月30日的第四季度及全财政年度的财务结果和业务进展。

以上内容来自Benzinga Earnings专栏,原文如下:

Financial Highlights from our Fiscal Year 2024:

  • Net sales totaled $19.5 million in fiscal 2024 or a decrease of 19.1% compared to $24.1 million in fiscal 2023.
  • Our gross profit for the year was flat at 62% in fiscal 2024 compared to 62% in fiscal 2023.
  • Our loss from operations was $3.3 million in fiscal 2024 as compared to a loss of $22.4 million in fiscal 2023.
  • Our non-GAAP adjusted EBITDA loss from operations in fiscal 2024 was approximately $1.5 compared to our non-GAAP adjusted EBITDA from operations in fiscal 2023 of approximately $5.5. million, despite the decline in revenue. Our non-GAAP adjusted EBITDA loss for the second half of 2024 was reduced to only $0.2 million from $1.2 million in the prior year comparative period.
  • Net loss attributable to common shareholders for fiscal 2024 was approximately $7.7 million or $1.79 per share as compared to a net loss for fiscal 2023 of approximately $26.9 million, or $13.30 per share. The improvement in fiscal 2024 was principally attributable to ongoing management's efforts on improving profitability, as well as the $13.2 million intangible impairment during 2023.
  • At September 30, 2024, we had working capital of approximately $1.1 million and cash on hand of approximately $2.4 million (which includes $4.7 million of accrued Series A dividend payments) as compared to working capital of approximately $3.4 million and cash on hand of approximately $1.8 million (which includes $0.67 million of accrued Series A dividend payments) at September 30, 2023.
  • We reported direct to consumer (DTC) net sales of $15.7 million or 80.4% of total net sales in fiscal 2024, a decrease of $3.9 million, or 19.9% from fiscal 2023.
  • As of the filing date of our annual report, the majority of our Notes have been converted and the balance of the Notes totaled approximately $0.36 million. When factoring in our cash balance of $2.4 million at the end of September 30, 2024 and ongoing cash consumption rate, management believe the Company has a strong liquidity position going into calendar 2025.

Pursuant to the disclosure requirements of the NYSE American Company Guide Section 610(b), cbdMD is reporting that its audited consolidated financial statements for the fiscal year ended September 30, 2024, included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 18, 2024, contains an audit opinion from its independent registered public accounting firm that includes an explanatory paragraph related to cbdMD's ability to continue as a going concern. This announcement does not represent any change or amendment to cbdMD's financial statements or to its Annual Report on Form 10-K for the fiscal year ended September 30, 2024.

We will host a conference call at 4:20 p.m., Eastern Time, on Wednesday, December 18, 2024, to discuss our September 30, 2024, fourth quarter and full fiscal year financial results and business progress.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法